C ognitive impairment has long been recognized as a symptom of schizophrenia, affective, and psychotic disorders. Until relatively recently, most research has focused on the severity, type, and course of impairment. As is reviewed in this series by Dr Alice M Saperstein and Dr Matthew M Kurtz, 1 we have learned that cognitive deficits are evident in most people with schizophrenia and schizoaffective disorders, evident even in the prodromal phase but seem to worsen around the time of first episode, and stable for many years, even as positive symptoms, such as hallucinations and delusions, wax and wane. Dr Christopher R Bowie, Ms Maya Gupta, and Ms Katherine Holshausen 2 report in this series that cognitive symptoms in the affective disorders appear to be more state related, though more than 60% of people with bipolar disorder (BD) continue to manifest cognitive dysfunction, even when clinically stable. Most studies comparing people with schizophrenia to nonpsychiatric samples find that cognitive test scores are on average 1.3 to 2.0 standard deviations below the mean, which means that 91% to 98% of the general population score higher. These deficits put patients at a considerable disadvantage when seeking employment and more generally facing the challenges of independent, productive living. Repeatedly, the research indicates that cognitive deficits are associated with functional outcome. It is for this reason that there is tremendous interest in finding ways to treat cognitive dysfunction.
In this In Review are 2 papers that provide an overview of the behavioural approaches that have been developed to address cognitive dysfunction in the psychotic and affective disorders. Dr Saperstein and Dr Kurtz 1 focus on cognitive remediation (CR) for schizophrenia, while Dr Bowie and colleagues 2 address how CR is being used to treat people with psychotic and nonpsychotic affective disorders. We learn from these 2 papers that the field of psychology is at a crossroads. No longer is there debate about whether people with schizophrenia can learn, or if cognitive skills are malleable. The research overwhelmingly supports the efficacy of CR for schizophrenia and schizoaffective disorder-when it is done in the context of a psychiatric rehabilitation model. The evidence base for using CR for people with nonpsychotic affective disorders is relatively smaller; nevertheless, CR for mood disorders is emerging as an effective nonpharmacological treatment option for improving cognitive performance in people with major depressive disorder and BD. Further, CR impacts not only cognition but also, as intended, it helps to improve psychosocial functioning and reduce disability.
Having established that cognitive deficits do respond to behavioural interventions, researchers are now tackling how to enhance the ability of CR to improve cognition, how to promote the transfer of cognitive gains to real-world functioning, and develop personalized treatments that are easily disseminated with fidelity. A tension has emerged as these issues are addressed. While there is tremendous enthusiasm for harnessing emerging knowledge about neuroplasticity to engineer more effective and efficient computer-based treatments, there is, simultaneously, a groundswell of support for integrating humanistic psychiatric rehabilitation principles into CR approaches to enhance functional outcomes. At their most extreme, these tensions emerge as camps. 3 One side, fuelled by the technology industry, advocates a medical model approach that uses US Food and Drug Administration-approved computer devices that dose cognitive exercises like medications. The other side, fuelled by person-centred advocacy, emphasizes psychotherapeutic approaches to address the many factors (for example, beliefs, motivation, and emotions) that promote transfer of learning to realworld behaviours.
The first large multisite study of CR in schizophrenia 4 chose the model of dosed, device-based computer exercises to test the effectiveness of CR, and the results failed to replicate the promising findings from a single-site trial of devicebased CR. 5 As is explained in both papers in this issue, 1, 2 there are decades of research indicating that learning, which is operationalized at a physiologic level as neuroplasticity, is a complex process, responsive to a multitude of factors. Converging evidence from the fields of neuroscience, education, motivation, and psychology indicate that people learn best not only when given opportunities to practice responding to new stimuli but also when they retain a sense of control and competency over the learning process, when relatedness needs are gratified, erroneous beliefs about learning are challenged, and there are opportunities to apply what is learned. 6, 7 Neuroplasticity is associated with both device-based interventions 3 and with more rehabilitationoriented, interactive CR. 8 Further, there is no evidence to suggest the relative superiority of devices or interactional learning experiences at promoting neuroplasticity. While it may be efficient multisite trial methodology to pay people to work at a computer station 4 to 5 hours a week, there is, as yet, an insufficient database to predict that it would be effective, or for that matter scalable in the community, as a comprehensive CR approach to enhance functional outcome.
Unfortunately, there is a considerable risk that the disappointing results of large multisite studies of devicebased CR will be taken as evidence that CR loses effectiveness when disseminated. That stance overlooks the many positive results of smaller multisite trials that used a more integrated approach to CR. It also overlooks the more promising approach to resolving the increasing tension in the field between device-and rehabilitation-oriented researchers. As similar as human brains are, the differences in learning are huge, and this speaks to a need to personalize the learning experience. Some people respond to CR, but at least one-third of subjects do not. 9, 10 To increase the effect sizes and number-needed-to-treat statistics, we need to consider the factors associated with a positive response to CR. Then, taking that information and applying the work on device development and rehabilitation practice, we can effect better treatment approaches. Better devices will improve CR outcomes when used in more rehabilitationoriented environments.
In this In Review, both papers highlight ways to integrate device and rehabilitation perspectives. Dr Bowie and colleagues 2 call for a greater range of device-delivered exercises and they recommend rehabilitation-oriented discussion topics that are more in line with the specificity and magnitude of impairment in mood disorders. They argue that many of the approaches for improving the severe and long-standing impairments in schizophrenia, whether drill-and-practice or compensatory, may be considered too monotonous or too facile for people with mood disorders. They also suggest that incorporating principles of cognitivebehavioural therapy to address nascent attitudes related to cognitive challenges may foster greater transfer of skills, just as skills training has done for schizophrenia. Further, they cite the need to delineate the pseudospecificity of cognitive change in mood disorders, which refers to the degree to which cognitive improvements truly reflect cognitive gains and are not artifacts of spurious changes associated with mood state.
Both papers emphasize the need to better understand mechanisms responsible for the generalization of CR to everyday behaviour change. Dr Saperstein and Dr Kurtz 1 suggest that as data on the neural basis of learning in people with schizophrenia become available, new technologies that harness the ability of the brain to make sustainable, functional changes may be integrated within a therapeutic context that promotes a personalized approach to learning. They discuss how application of both device and rehabilitation techniques to enhance motivation and learning during CR has boosted CR outcomes. Together, these papers offer a convincing case that it will be possible to develop transportable and scalable methods of CR that maximize the ability of people with psychotic disorders to improve cognition and achieve personal goals for recovery.
